Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Revance Therapeutics, Inc. - Common Stock (NQ:RVNC)

3.650 UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Revance Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2022 ↗
Upgrades 
Via Benzinga
News headline image
What 6 Analyst Ratings Have To Say About Revance Therapeutics ↗
Revance Therapeutics (NASDAQ:RVNC) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
  
Via Benzinga
News headline image
Relay Therapeutics, Rent the Runway And Some Other Big Stocks Moving Lower In Today's Pre-Market Session ↗
U.S. stock futures traded higher this morning ahead of the much-awaited inflation data for August. Here are some big stocks moving lower in today’s pre-market trading session. 
Via Benzinga
News headline image
With New Growth Avenues, Analysts Boost Price Targets For This Botox Competitor ↗
 
Via Benzinga
News headline image
Analyst Ratings for Revance Therapeutics ↗
Revance Therapeutics (NASDAQ:RVNC) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Why SeaChange International Is Trading Higher By Around 15%; Here Are 26 Stocks Moving Premarket ↗
Gainers Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) rose 41.7% to $2.72 in pre-market trading. Comera Life Sciences Form 4 filing showed multiple insiders purchased 122,600 shares at an average... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers OpGen (NASDAQ:OPGN) shares rose 20.6% to $0.52 during Monday's after-market session. This security traded at a volume of 927.4K shares come close, making up 324.6% of its average volume over... 
Via Benzinga
News headline image
Needham Maintains Buy Rating for Revance Therapeutics: Here's What You Need To Know ↗
Needham has decided to maintain its Buy rating of Revance Therapeutics (NASDAQ:RVNC) and raise its price target from $25.00 to $35.00. Shares of Revance Therapeutics are trading up 9.72% over the last... 
Via Benzinga
News headline image
What 5 Analyst Ratings Have To Say About Revance Therapeutics ↗
Revance Therapeutics (NASDAQ:RVNC) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
5 Analysts Have This to Say About Revance Therapeutics ↗
Within the last quarter, Revance Therapeutics (NASDAQ:RVNC) has observed the following analyst ratings: 
Via Benzinga
News headline image
New 483 Observations Unlikely to Impact Much Awaited Revance's Daxi Approval, Says This Analyst ↗
 
Via Benzinga
News headline image
Revance Therapeutics: Q2 Earnings Insights ↗
  Revance Therapeutics (NASDAQ:RVNC) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday ↗
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 176.5% to close at $31.00 on Thursday after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to... 
Via Benzinga
News headline image
Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary ↗
 
Via Benzinga
News headline image
Recap: Revance Therapeutics Q1 Earnings ↗
Revance Therapeutics (NASDAQ:RVNC) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Why Bilibili Is Trading Lower By Over Around 14%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 73.8% to $19.48 after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to shareholders. 
Via Benzinga
News headline image
AAPL Stock Alert: 13 Takeaways From the Latest Apple Event 2022 ↗
Apple (AAPL) stock is a hot topic on Thursday following the tech giant's latest event showing off new products and we've got the details! 
Via InvestorPlace
News headline image
Why Is Revance Therapeutics (RVNC) Stock Soaring Today? ↗
RVNC stock is jumping 12% after the FDA approved its alternative to AbbVie's Botox. Revance's injection is supposed to last longer than Botox. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
  
Via Benzinga
News headline image
Revance Shares Shoot Higher As FDA Cleared DAXXIFY Injection For Frown Lines ↗
The United States Food and Drug Administration (FDA) has approved Revance Therapeutics’ (NASDAQ: RVNC) lead asset DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the temporary improvement of... 
Via Benzinga
News headline image
Why Asana Is Trading Higher By 24%; Here Are 24 Stocks Moving Premarket ↗
Gainers Asana, Inc. (NYSE: ASAN) rose 24.1% to $23.62 in pre-market trading after the company reported better-than-expected results for its second quarter and issued a strong sales guidance. 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know ↗
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar. 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
  This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
Revance Therapeutics: Earnings Outlook ↗
  Revance Therapeutics (NASDAQ:RVNC) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement. 
Via Benzinga
News headline image
Revance Therapeutics's Return On Capital Employed Insights ↗
Benzinga Pro data, Revance Therapeutics (NASDAQ:RVNC) reported Q1 sales of $25.26 million. Earnings fell to a loss of $64.34 million, resulting in a 1.97% decrease from last quarter. 
Via Benzinga
News headline image
Earnings Scheduled For August 9, 2022 ↗
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter. 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Earnings Scheduled For May 10, 2022 ↗
Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.